The Malta Conferences address the shared desire to improve quality of life and political stability in the Middle East through scientific collaboration
Nes Ziona, Israel, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage immunotherapy company, today reported positive top-line results of an investigator-initiated clinical trial of AllocetraTM in COVID-19 patients in severe/critical condition.
Original post:
Enlivex Reports Positive Allocetra Trial Results in COVID-19 Patients in Severe/Critical Condition
WALTHAM, Mass. and HALLE (Saale), Germany, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, and Navigo Proteins GmbH (“Navigo”), a premier protein engineering company specializing in novel affinity ligand development, today announced their successful development of an affinity ligand targeting the spike protein, to be utilized in the purification of COVID-19 vaccines. The program has entered stage two, which is focused on both scaling up the manufacturing of this ligand, and on the development and validation of the related affinity chromatography resin. The affinity resin aims to provide end users with a rapid, high purity capture step, decreasing processing time and potentially improving overall yield in the manufacturing of critical COVID-19 vaccines. Repligen anticipates that the final resin product will be commercially available in early 2021.
Read the original post:
Repligen and Navigo Proteins Announce Achievement of Key Milestone in Developing an Affinity Resin for the Purification of COVID-19 Vaccines
Orphazyme A/SCompany announcement No. 60/2020 Company Registration No. 32266355
See the original post here:
Major shareholder announcement
CAMBRIDGE, Mass., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced it will present multiple posters on the company’s ongoing studies in patients with facioscapulohumeral muscular dystrophy (FSHD) during the 25th International Congress of the World Muscle Society.
Go here to read the rest:
Fulcrum Therapeutics Announces Multiple Presentations During the Virtual 25th International Congress of the World Muscle Society
STAMFORD, Conn., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced the appointment of Thomas Reilly as Chief Financial Officer, effective October 1, 2020. Mr. Reilly will be responsible for overseeing the Company’s financial strategy and activities related to accounting, capital markets, and business operations. He joins Cara from Allergan, now part of AbbVie, where he served as Finance Head for the U.S. General Medicine Commercial Business.
Excerpt from:
Cara Therapeutics Appoints Thomas Reilly as Chief Financial Officer
BOSTON, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, announced the appointment of Sachiyo Minegishi as chief financial officer, effective today. In addition, the company announced that Jennifer Wellman has been promoted to chief operating officer, from her prior role as senior vice president of regulatory and quality.
Read the rest here:
Akouos Announces Key Leadership Appointments
ZILXI is the First FDA Approved Minocycline Product for the Treatment of Inflammatory Lesions of Rosacea in Adults
Accepted Abstract will Showcase Clinical Data on Investigational Drug Rhenium NanoLiposomes (RNL™) Accepted Abstract will Showcase Clinical Data on Investigational Drug Rhenium NanoLiposomes (RNL™)
See the article here:
ReSPECT Glioblastoma Clinical Trial Data to be Presented at 2020 Society for Neuro-Oncology Annual Meeting
COPENHAGEN, Denmark, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Evaxion Biotech, a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies and vaccines, announces today that it has received DKK 4.8 million (approx. $800,000) in funding from Innovation Fund Denmark for the development of its new RAVEN platform, an integral part of Evaxion’s Adaptive and Intelligent Vaccine for a Rapid Response against Corona Viruses (AICoV) program.
Continued here:
Evaxion Biotech Launches New AI Powered Platform, RAVEN, to Enable Faster Response to Emerging Viral Pandemics